Rockefeller, Broad Settle CRISPR IP Dispute; EPO Denies Broad European Patent – GenomeWeb
FierceBiotech |
Rockefeller, Broad Settle CRISPR IP Dispute; EPO Denies Broad European Patent
GenomeWeb This article has been updated from a previous version to include a statement from ERS Genomics on the EPO’s decision regarding the Broad Institute’s European patents. NEW YORK (GenomeWeb) – Rockefeller University and the Broad Institute said this week … Arbitrator tells Rockefeller to stop blocking Broad Institute of MIT and Harvard CRISPR-Cas9 system patentScience Codex |
Myeloma Research News |
First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple myeloma, the therapy’s developer, Poseida Therapeutics, announced. The trial (NCT03288493), which will test the safety … |
Phys.Org |
Using electric fields to manipulate droplets on a surface could enable high-volume, low-cost biology experiments
Phys.Org I noticed this problem three years ago, when I was at a synthetic biology company where I built some of these microfluidic systems and mechanical machines that interact with them. I had to babysit these machines to make sure they didn’t explode … |
|
New CRISPR method could take gene editing to the next level
New Scientist The CRISPR genome-editing method may just have become even more powerful. Uri David Akavia’s team at McGill University in Canada has managed to repair mutations in 90 per cent of target cells using CRISPR – the best success rate yet. The CRISPR … |